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Abstract
Background: Endothelial inflammatory responses mediated by Toll-like receptors (TLRs), particularly TLR2 and TLR4,
play an important role in atherogenesis. While Type 1 diabetes (T1D) promotes the development and progression
of atherosclerosis, the effect of T1D on TLR2/4-mediated inflammatory responses in coronary artery endothelial
cells (CAECs) remains unclear.
Methods: We tested the hypothesis that diabetic CAECs have enhanced inflammatory responses to TLR2/4
stimulation. Non-diabetic and diabetic CAECs were treated with TLR2 agonist peptidoglycan and TLR4 agonist
lipopolysaccharide. The expression of ICAM-1, IL-6 and IL-8 were analyzed by real-time PCR, immunoblotting and
ELISA, and NF-B activation by immunoblotting and immunostaining. In additional experiments, insulin was added
before TLR stimulation to determine whether insulin deficiency alone is responsible for the alteration of TLR2/4-
mediated inflammatory responses.
Results: Stimulation of TLR2 or TLR4 induced NF-B activation, and the expression of ICAM-1, IL-6 and IL-8.
Interestingly, the expression of inflammatory mediators was significantly enhanced in diabetic cells. The enhanced
inflammatory responses correlated with augmented NF-B activation in the absence of a change in TLR2 or TLR4
protein levels. Further, pretreatment of diabetic cells with insulin failed to suppress the enhanced inflammatory
responses.
Conclusions: Diabetic CAECs have enhanced inflammatory responses to stimulation of TLR2 or TLR4, and insulin
alone is insufficient to correct the hyper-inflammatory responses. The mechanism underlying the enhanced
inflammatory responses appears to be augmentation of pro-inflammatory signaling, rather than up-regulation of
levels of TLR2 and TLR4. These findings suggest that diabetic CAECs adopt a hyper-inflammatory phenotype and
that this endothelial phenotypic change may predispose coronary artery to atherogenesis.
Background
Growing evidence supports an important role for vascu-
lar local inflammation in the development and progress
of atherosclerosis [1-3]. Endothelial cells are important
in immune and inflammatory responses [4,5], and
inflammatory activation of the endothelial cells is a criti-
cal step in the development of atherosclerosis [1,3]. In
the Type 1 diabetes (T1D) population, atherogenesis
occurs in younger ages and advances faster [6,7]. How-
ever the underlying mechanisms are incompletely
understood.
Toll-like receptors (TLRs) are pathogen pattern recog-
nition receptors that recognize bacterial and viral pro-
ducts, and other pathogens [8]. Activation TLR2 or
TLR4 by microbial ligands induce a cascade of intracel-
lular signaling events, culminating in the production of
pro-inflammatory mediators. Thus, TLR2 and TLR4
have a central role in innate immunity and inflammation
[9]. A number of studies demonstrate that these two
major innate immune receptors play a mechanistic role
in the development of atherosclerosis [10-12]. In addi-
tion, TLR2 ligand peptidoglycan (PGN) and TLR4 ligand
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any medium, provided the original work is properly cited.lipopolysaccharide (LPS) have been found in vessels with
early atherosclerotic lesions [13,14]. While these bacter-
ial agents induce the production of multiple pro-
inflammatory mediators in mononuclear cells [15,16],
their effects on the inflammatory responses in coronary
artery endothelial cells (CAECs) remain to be deter-
mined. Investigation of the effect of T1D on CAEC
inflammatory responses to TLR2/4 stimulation could
provide insights into the mechanisms underlying the
pro-atherogenic phenotype associated with this disease.
TLR2 and TLR4 have also been implicated in the
pathophysiology of T1D. In an experimental T1D
model, TLR2 is involved in the autoimmune inflamma-
tion in the pancreatic islet [17]. The expression of
TLR2, as well as TLR3, TLR4 and TLR5 in bone mar-
row-derived macrophages is increased in diabetic NOD
mice [18]. Insulin is found to suppress the expression of
TLR2 in mononuclear cells at the transcriptional level
[19]. In addition, altered TLR4 function is involved in
the inflammation in B cells from diabetes mellitus
patients by two mechanisms: elevation of pro-inflamma-
tory IL-8 and lack of anti-inflammatory/protective IL-10
production [20]. While these studies indicate altered cel-
lular TLR expression and responses associated with
T1D, it remains unclear whether TLR2/4 levels and the
inflammatory responses to TLR2/4 agonists are altered
in CAECs from T1D patients.
We hypothesized that CAECs of T1D patients have
enhanced inflammatory responses to TLR2/4 stimulation.
The purposes of this study are to determine: 1) the effect
of PGN and LPS on the inflammatory responses in human
CAECs, 2) whether TLR2/4 levels, signaling and TLR2/4-
mediated expression of pro-inflammatory mediators are
altered in CAECs from T1D patients, and 3) the effect of
insulin on the inflammatory responses in diabetic CAECs.
Methods
Chemicals and reagents
Staphylococcus aureus PGN and E coli LPS were
purchased from Sigma-Fluka (St. Louis, MO, USA).
Human CAECs from non-diabetic and diabetic donors
(information in Table 1) were purchased from Lonza
(Boulder, CO, USA). Protein assay reagents and ECL
immunoblotting substrate were purchased from Pierce
(Rockford, IL, USA). The following antibodies were used
for Western-blot analysis: rabbit anti-human intercellular
adhesion molecule (ICAM)-1 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), monoclonal rabbit anti-human
TLR2 (Imgenex, San Diego, CA, USA), monoclonal rab-
bit anti-human TLR4 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), rabbit anti-human phosphor-nuclear
factor kappa B (NF-B) p65 (Cell Signaling, Boston,
MA), rabbit anti-human total NF-B p65 (Cell Signaling,
Boston, MA, USA), rabbit anti-human beta-actin (Cell
Signaling, Boston, MA, USA), and rabbit anti-mouse
ICAM-1 (Santa Cruz Biotechnology, Santa Cruz, CA,
U S A ) .R N e a s ym i c r ok i tw a sp u r c h a s e df r o mQ i a G e n
(Valencia, CA, USA). IL-6 and IL-8 ELISA kits were pur-
chased from R&D Systems (Minneapolis, MN, USA).
Animals
TLR2 knockout (TLR2 KO), C57BL/6 (WT), and C3H/
HeJ (TLR4-defective) mice were purchased from Jackson
Laboratory (Bar Harbor, MA, USA), and male C3H/
HeN (TLR4-competent) mice were purchased from
Charles River Laboratories (Wilmington, MA, USA).
The mice were 12 weeks old and acclimated in a quar-
antine room for 2 weeks before experiments, and main-
tained on a standard pellet diet. Their body weight was
23 to 28 g when used for the experiments. All experi-
ments were approved by the Animal Care and Research
Committee of the University of Colorado Denver, and
this investigation conforms to The Guide for the Care
and Use of Laboratory Animals (National Research
Council, revised 1996).
Culture of human CAECs
Cells were grown in endothelial cell growth medium
(EBM-2 from Lonza, Boulder, CO, USA) supplemented
with EGM-2 (2% fetal cattle serum, hydrocortisone,
human fibroblast growth factor, vascular endothelial
growth factor, insulin-like growth-factor, ascorbic acid,
epidermal growth factor, gentamicin/amphotericin-1000,
and heparin).
For the experiments, cells were seeded in 500 μlc o m -
plete medium in 24-well plates. After growing to conflu-
ence, medium was changed completely. PGN and LPS
was diluted in complete cell culture medium and added
to the cells. The final concentrations of PGN and LPS
were 10 μg/ml and 200 ng/ml, respectively. In additional
experiments, human insulin (from Sanofi Aventis,
Bridgewater, NJ, USA, final concentration 10 or 100 U/l)
was added to the cells 1 h prior to adding PGN or LPS.
Isolation and culture of mouse coronary vascular
endothelial cells
Mouse coronary vascular endothelial cells were isolated
according to Li’s method [21]. Briefly, hearts were briefly
Table 1 Details of the human CAECs used in this study
Cells used Lot number Donor Initiation passage Passage used
Non-diabetic 3F0239 25y, ♂ 3 4-6
Non-diabetic 7F4019 56y, ♂ 3 4-6
Non-diabetic 7F4249 36y, ♂ 3 4-6
T1D 7F3422 56y, ♂ 3 4-6
T1D 7F4021 57y, ♂ 3 4-6
T1D 7F3795 34y, ♂ 3 4-6
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Page 2 of 11dipped into 70% ethanol to devitalize epicardial
mesothelial cells and endocardial endothelial cells. Ven-
tricular tissue was minced into approximately 1.0 mm
3
pieces, and digested at 37°C for 10 min in 2.0 ml of
norminally calcium-free Hank’s balanced salt solution
(HBSS) supplemented with collagenase II (1.0 g/l, glu-
cose (2.0 g/l), taurine (2.5 g/l), bovine serum albumin
( B S A ,0 . 1 % ) ,a n dM g C l 2 (1.4 mM). Then, the tissue pel-
let was re-suspended in a second digestion solution con-
taining 0.125% trypsin, 0.1 mM EDTA and 2.0 g/l
glucose dissolved in HBSS, and incubated at 37°C for 10
min with shearing by pipetting once every 3 min. At the
end of this digestion, the supernatant was transferred
into a 15 ml Falcon tube containing 1.0 ml of FBS, and
cells were separated from tissue debris and remaining
myocytes by spinning at 500 rpm for 5 min. The super-
natant was centrifuged at 1,200 rpm (4°C) for 8 min to
collect endothelial cells. The cells were resuspended in
10 ml Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 20% FCS, penicillin (50,000U/l) and
streptomycin (50 g/l). Cells were seeded in 500 μlc o m -
plete medium in 24-well plates and cultured at 37°C for
2 h. Then, non-attached cells were removed by changing
medium. Cells of 90% confluence were treated with
PGN or LPS as described for human cells.
Immunoblotting
Immunoblotting was used to detect ICAM-1, phosphory-
lated NF-B p65, total NF-B p65, TLR2, TLR4 and beta-
actin. After treatment, CAECs were washed three times
with cold PBS, and then lysed with lysis buffer (protease
inhibitor cocktail and Mammalian Protein Extraction
Reagent, Thermo Scientific, Waltham, MA, USA). Samples
were separated on 4-20% SDS-polyacrylamide gels (Bio-
Rad, Hercules, CA, USA) and transferred onto nitrocellu-
lose membranes. Membranes were blocked for 1 h at
room temperature with 5% dry milk in TPBS (PBS con-
taining 0.1% Tween 20), and then incubated with the
appropriate primary antibodies (ICAM-1 antibody was
diluted 1:200, beta-actin 1:1000, and all others 1:500) over-
night at 4°C. After washing with TPBS, membranes were
incubated with horseradish peroxidase (HRP)-linked sec-
ondary antibodies (1:5000 dilution with TPBS containing
5% dry milk) at room temperature for 1 h. Bands were
developed using ECL and exposed on X-ray films. Band
density was analyzed using NIH ImageJ software.
Cytokine ELISA
Cytokine concentrations in cell culture supernatants
were quantified by ELISA kits (R&D Systems, Minnea-
polis, MN, USA) as previously reported [22]. Recombi-
nant cytokines were used to construct standard curves.
Absorbance of standards and samples was determined
spectrophotometrically at 450 nm using a microplate
reader (Bio-Rad, Hercules, CA, USA). Results were
plotted against the standard curve. The assays were car-
ried out according to the protocols provided by the
manufacturer.
Immunofluorescent staining
Immunofluorescent staining was performed as
previously reported to examine NF-B intranuclear
translocation in CAECs [23]. Briefly, cells were cultured
in 8-well chamber slides to 40-50% confluence. Cells
were stimulated with PGN or LPS for 30 or 60 min.
After washing with cold PBS, cells were treated with a
mixture of 30% methanol and 70% acetone at room
temperature for 5 min and fixed in PBS-buffered 3.5%
paraformaldehyde at room temperature for 10 min.
After washing with PBS, cells were blocked with 10%
donkey serum for 30 min. Then, cells were incubated
for 2 h with a rabbit polyclonal antibody against NF-B
p65. Control cells were incubated with non-immune
rabbit IgG. After washing with PBS, cells were incubated
Cy3-conjugated donkey anti-rabbit IgG for 1 h to label
NF-B p65 red. Nuclei were counter-stained blue with
bis-benzimide. Photography was performed with a Leica
DMRX microscope (Wetzlar, Germany).
RNA-isolation and real-time RT-PCR
Confluent CAECs were treated with PGN or LPS for 1
or 2 h. Thereafter cells were harvested with lysis buffer,
and mRNA was extracted using a Qiagen RNeasy Mini
Kit (Valencia, CA, USA). cDNA was prepared by reverse
transcription (SuperScript III First-Strand, Invitrogen,
Carlsbad, CA, USA). Real-time PCR was performed as
previously reported using Power Sybr Green PCR Mas-
ter Mix (Applied Biosystems, Foster City, CA, USA)
with Corbbet Cycler (Qiagen, Valencia, CA, USA) [24].
Each reaction was carried out for 45 or 50 cycles in a
total volume of 15 μl( 4 . 9μlH 2 O ,7 . 5μl Sybr Green
Mix, 0.3 μlo fe a c h5m Mp r i m e r ,2 . 0μlc D N A ) .T h e
following sets of primers were used to amplify specific
cDNA fragments: GAPDH (forward: 5’-GGC TCT CCA
GAA CAT CAT CC; reverse:5’-TTT CTA GAC GGC
AGG TCA GG-3’); ICAM-1 (forward: 5’-AGC TTC
TCC TGC TCT GCA AC; reverse: 5’-GTC TGC TGG
GAA TTT TCT GG); IL-8 (forward:5’-CTC TTG GCA
GCC TTC CTG ATT; reverse: 5’-TAT GCA CTG ACA
TCT AAG TTC TTT AGC A); IL-6 (forward: 5’-CAT
CCA TCT TTT TCA GCC ATC TTT; reverse: TGA
CAA ACA AAT TCG GTA CAT CCT).
Statistics
Data are expressed as mean ± standard error of mean
(SEM). Analysis of variance (ANOVA) was performed,
and differences were considered significant when P <
0.05, as verified by Fisher post-hoc test.
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Diabetic CAECs express higher levels of ICAM-1 in
response to stimulation of TLR2 and TLR4
We determined the effects of PGN and LPS on ICAM-1
expression in non-diabetic and T1D CAECs. Stimulation
of cells with PGN or LPS induced the expression
of ICAM-1 in both non-diabetic and diabetic CAECs
(Figure 1A and 1B). While ICAM-1 protein levels
increased by 4.9 folds in non-diabetic cells, it increased
by 6.9 folds in diabetic cells following PGN stimulation
(Figure 1A). Similarly, LPS stimulation resulted in a
more robust increase in ICAM-1 protein levels in dia-
betic cells (Figure 1B). Further, diabetic cells exhibited a
greater increase in ICAM-1 mRNA levels after stimula-
tion with either PGN or LPS (Figure 1C). Therefore,
diabetic CAECs have enhanced ICAM-1 responses to
PGN and LPS.
We examined whether PGN and LPS exert an effect
on coronary vascular endothelial cells through TLR2
and TLR4, respectively. We stimulated mouse coronary
vascular endothelial cells with PGN or LPS for 24 h and
examined cellular ICAM-1 protein levels. As shown in
Figure 2, stimulation with PGN increased ICAM-1 levels
by 6.3 folds in coronary vascular endothelial cells from
wild-type mice, and LPS induced a 9.0-fold increase in
cellular ICAM-1 levels. In contrast, the effect of PGN
was essentially absent in TLR2 KO cells, and effect of
LPS was markedly reduced in TLR4-defective cells.
Thus, PGN induces an inflammatory response in coron-
ary vascular endothelial cells through TLR2, and the
effect of LPS is TLR4-dependent.
Diabetic CAECs release greater amounts of IL-6 and IL-8
in response to stimulation of TLR2 or TLR4
We analyzed IL-6 and IL-8 levels in culture superna-
tants with or without exposing CAECs to PGN or LPS
for 24 h. Interestingly, diabetic cells released more IL-6
(248.7 ± 36.9 vs. 165.1 ± 27.9 in non-diabetic cells) and
IL-8 (348.2 ± 38.2 vs. 132.6 ± 10.9 in non-diabetic cells)
in baseline although the differences from the baseline
A
B
C
Figure 1 Diabetic CAECs express higher levels of ICAM-1 after stimulation with PGN and LPS. A and B. Non-diabetic and diabetic CAECs
were stimulated with PGN (10 μg/ml) or LPS (200 ng/ml) for 24 h, and ICAM-1 protein levels were analyzed by immunoblotting. Diabetic cells
exhibited a greater increase in ICAM-1 protein levels. C. Non-diabetic and diabetic CAECs were stimulated with PGN (10 μg/ml) or LPS
(200 ng/ml) for 2 h and analyzed for ICAM-1 mRNA levels by real time RT-PCR. Diabetic cells expressed higher levels of ICAM-1 mRNA. Results
are expressed as Mean ± SEM; n = 5; *P < 0.05 vs. control; #P < 0.05 vs. non-diabetic cells treated with LPS or PGN.
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release of IL-6 and IL-8 peptides increased in non-
diabetic and diabetic cells following stimulation with
PGN or LPS (Figure 3A). However, IL-6 and IL-8 levels
in the supernatants of diabetic CAECs were 3.36 and
1.48 folds, respectively, of those of non-diabetic CAECs
following stimulation of TLR2, and IL-6 and IL-8 levels
following TLR4 stimulation were 1.44 and 0.63 folds
higher, respectively, in diabetic cells. The enhanced
release of IL-6 and IL-8 peptides in diabetic cells corre-
lated with augmented expression of IL-6 and IL-8
mRNA at 1 and 2 h of TLR2/4 stimulation, as revealed
by real-time RT-PCR (Figure 3B). Together, these
results show that T1D CAECs have enhanced inflamma-
tory responses to stimulation TLR2 and TLR4.
TLR2 and TLR4 levels are unaltered in T1D CAECs
We examined whether the enhanced inflammatory
responses to TLR2/4 stimulation are associated with ele-
vated levels of these two receptors in T1D CAECs.
Representative immunoblots in Figure 4 show that levels
of TLR2 and TLR4 proteins were comparable between
non-diabetic cells and diabetic cells in conditions with
and without receptor agonists. It appears that the
enhanced inflammatory responses to TLR2/4 stimula-
tion in diabetic cells are not due to alterations in the
protein levels of these two innate immune receptors.
NF-B activation is augmented in diabetic CAECs
following stimulation of TLR2 and TLR4
To understand the mechanism underlying the enhanced
inflammatory responses to TLR2/4 stimulation in dia-
b e t i cC A E C s ,w ee x a m i n e dN F - B phosphorylation and
intranuclear translocation. Stimulation of TLR2 or TLR4
induced greater phosphorylation of NF-Bp 6 5i nd i a -
betic CAECs at 30 to 120 min (Figure 5A and 5B). Simi-
larly, diabetic CAECs exhibited more pronounced
intranuclear NF-B p65 after stimulation of TLR2 and
TLR4 (Figure 5C, images at 60 min are shown). The
results show that the enhanced inflammatory responses
to stimulation of TLR2/4 in diabetic CAECs are asso-
ciated with augmented pro-inflammatory signaling.
Insulin alone fails to suppress the inflammatory
responses to TLR2 and TLR4 stimulation in T1D CAECs
Insulin has been found to have an anti-inflammatory effect
in macrophages [25]. We determined the effect of insulin
on the enhanced inflammatory response in diabetic
CAECs. Human insulin was added to culture medium, in
final concentrations of 10 or 100 U/l, 1 h prior to the addi-
tion of PGN or LPS. As shown in Figure 6, insulin at
10 U/l (approximately 400 folds of normal blood insulin
levels) had no effect on ICAM-1, IL-6 and IL-8 levels fol-
lowing stimulation with either PGN or LPS. Further, insu-
lin at 100 U/l did not affect LPS-induced production of
ICAM-1, IL-6 and IL-8 although this higher concentration
of insulin reduced ICAM-1 and IL-6 levels after stimula-
tion with PGN (Figure 6). Thus, treatment with insulin
alone is insufficient to correct the hyper-inflammatory
phenotypic change in diabetic CAECs.
Discussion
In this study, we demonstrated that diabetic CAECs
have enhanced inflammatory responses to TLR2 and
TLR4 agonists with increased expression of ICAM-1,
IL-6 and IL-8. The hyper-inflammatory phenotype of
diabetic CAECs is characterized by augmented NF-B
activation in response to TLR2/4 agonists in the absence
of altered cellular TLR2/4 levels. Insulin alone is insuffi-
cient to correct the hyper-inflammatory responses in
T1D CAECs.
Diabetic CAECs have enhanced inflammatory responses
to TLR2/4 agonists
T h ei n n a t ei m m u n i t yi st h ef i r s tl i n eo fd e f e n s ea g a i n s t
microorganisms and also plays an important role in
A                                         B 
                        
Figure 2 Induction of ICAM-1 expression in coronary endothelial cells by PGN and LPS requires TLR2 and TLR4, respectively.
A. Coronary endothelial cells isolated from TLR2 KO and wild type (C57BL/6) mice were treated with PGN (10 μg/ml) for 24 h. A representative
immunoblot shows that PGN induced a robust increase in ICAM-1 levels in wild type cells, but it had a minimal effect on ICAM-1 levels in TLR2
KO cells. B. A representative immunoblot shows that induction of ICAM-1 expression by LPS (200 ng/ml, 24 h) is markedly reduced in coronary
endothelial cells from TLR4-defective (C3H/HeJ) mice.
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C                                                  D
E                                                  F 
Figure 3 Diabetic CAECs produce and release greater amounts of IL-6 and IL-8 in response to TLR2 and TLR4 stimulation. Non-diabetic
and diabetic CAECs were stimulated with PGN (10 μg/ml) and LPS (200 ng/ml) for 1, 2 or 24 h. Levels of IL-6 and IL-8 peptides (A and B)i n
medium were assessed by ELISA after treatment for 24 h, and mRNA levels in cell lysates (C, D, E and F) were analyzed with real-time PCR after
treatment for 1 or 2 h. After stimulation of either TLR2 or TLR4, diabetic cells expressed higher levels of IL-6 and IL-8 mRNA and released greater
amounts of IL-6 and IL-8. Results are expressed as Mean ± SEM; n = 5; *P < 0.05 vs. control; #P < 0.05 vs. non-diabetic cells treated with LPS
or PGN.
A
B
Figure 4 TLR2 and TLR4 protein levels in diabetic CAECs are not altered. Non-diabetic and diabetic CAECs were untreated or stimulated
with PGN (10 μg/ml) or LPS (200 ng/ml) for 24 h. Representative immunoblots shows comparable TLR2 (A) and TLR4 (B) levels in non-diabetic
and diabetic cells with and without stimulation. Results are expressed as Mean ± SEM; n = 5.
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TLRs, acting as pathogen-recognition receptors, are
important components of the innate immune system
[8,28]. Endothelial innate immune responses are key
events in vascular inflammation and the development of
atherosclerosis [29]. Previous studies have examined the
TLR4-mediated endothelial inflammatory responses
[30,31]. In this study, we present novel findings that sti-
mulation of TLR2 in human CAECs with bacterial PGN
also induces the expression of adhesion molecule
(ICAM-1), cytokine (IL-6) and chemokine (IL-8). These
TLR2-mediated inflammatory responses in human
A
B
C
Figure 5 NF-B activation by TLR2 and TLR4 is augmented in diabetic CAECs. Non-diabetic and diabetic CAECs were stimulated with PGN
(10 μg/ml) and LPS (200 ng/ml) for 10, 30, 60 or 120 min. A and B. Representative immunoblots show that stimulation of either TLR2 or TLR4
induced greater phosphorylation of NF-B p65 in diabetic cells at 30 to 120 min. C. NF-B p65 was label red by immunostaining with a specific
antibody, and nuclei were counter-stained blue with bis-benzimide. Representative immunofluorescent images show more intranuclear NF-B
p65 in diabetic cells at 60 min after stimulation of TLR2 or TLR4.
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stimulation with LPS. Importantly, we found that
diabetic CAECs have enhanced inflammatory responses
to both TLR2 and TLR4 agonists. Therefore, T1D
enhances the inflammatory responses to TLR2 and
T L R 4s t i m u l a t i o ni nC A E C s .H o w e v e r ,t h i ss t u d yw a s
performed using cells from a small group of diabetic
donors. Large scale studies are needed to further vali-
date these findings. Since chemokines and adhesion
molecules play a crucial role in atherogenesis through
g
A
B
Figure 6 Insulin has a minor effect on the hyper-inflammatory responses to TLR2 stimulation, but does not affect those to TLR4
stimulation in diabetic CAECs. Insulin (10 or 100 U/l) was added to diabetic CAEC cultures 1 h prior to addition of PGN (10 μg/ml) or LPS (200
ng/ml). Cellular ICAM-1, IL-6 and IL-8 levels were analyzed at 24 h after addition of PGN or LPS. Insulin in a concentration of 10 U/l had no effect
on ICAM-1, IL-6 and IL-8 levels following stimulation with either PGN or LPS. Higher concentration of insulin reduced ICAM-1 and IL-6 levels after
stimulation with PGN (A), but did not affect LPS-induced production of ICAM-1, IL-6 and IL-8 (B). Results are expressed as Mean ± SEM; n = 5; *P
< 0.05 vs. control.
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decreased in association with reduction of inflammation
[32], our results indicate that the pro-inflammatory
phenotypic change in CAECs may contribute to the
mechanisms underlying the higher risk for atherogenesis
in T1D patients. A number of studies demonstrate that
T1D has a variety of effect on vascular biology [33].
Recent reports described effects of diabetes on circulat-
ing smooth muscle progenitor cell differentiation and
vascular smooth muscle cell calcium handling [34,35].
The findings of the present study indicate that T1D may
enhance the inflammatory responses of coronary artery
to pathogen patterns.
TLR2 recognizes lipoproteins and PGN from gram-
positive bacteria, and TLR4 recognizes LPS from gram-
negative bacteria [9,36]. It has been reported that higher
eukaryotes have other PGN recognition proteins includ-
ing CD14, Nod1 and Nod2 that induce host responses
to bacteria [37]. In addition, CD14 is also involved in
cellular responses to LPS [38]. We determined the role
of TLR2 and TLR4 in cellular responses to PGN and
LPS in coronary endothelial cells. We found that PGN
and LPS induced ICAM-1 expression in wild-type cells.
However, PGN had no effect on TLR2 KO cells, and
LPS had a minimal effect on TLR4-defective cells. These
results confirmed that PGN induces the inflammatory
responses in coronary vascular endothelial cells through
the TLR2 pathway, and the effect of LPS in this cell
type is TLR4-dependent.
The enhanced inflammatory responses in diabetic CAECs
are associated with augmented NF-B activation, but not
an alteration of TLR2/4 levels
The main consequence of stimulation of TLR2 and
TLR4 is the activation of NF-B, which mediates the
expression of cytokines, chemokines and adhesion mole-
cules [39]. Pro-inflammatory cytokines induced by
NF-B also cause the activation of NF-B, forming a
positive regulatory loop to amplify the inflammatory
responses [39,40]. In this study, we found that stimula-
tion of TLR2 or TLR4 induces more pronounced NF-B
phosphorylation and intranuclear translocation in dia-
betic CAECs. The augmented NF-B activation should
play an important role in the enhancement of inflamma-
tory responses in diabetic CAECs. The mechanisms
underlying the enhanced NF-B activation in diabetic
CAECs remain unclear from this study. A change in
TLR2/4 distribution, affinity to ligand or signaling to the
MyD88 pathway could alter NF-B activation in diabetic
cells.
Interestingly, TLR2 and TLR4 protein levels in diabetic
CAECs are not different from those in non-diabetic cells,
either in the baseline or after stimulation. The results
indicate that the enhancement of TLR2/4-mediated
inflammatory responses in human CAECs by T1D does
not involve an increase in cellular levels of TLR2 and
TLR4 protein. Previous studies found increased levels of
TLR2 and TLR4 in circulating monocytes in T1D
patients [41]. It appears that the impact of T1D on cellu-
lar TLR2 and TLR4 levels is specific to certain cell types.
It remains unclear from this study how NF-B activation
is augmented in T1D CAECs. One possible mechanism is
that the availability of TLR2/4 is altered. Further studies
are needed to examine whether subcellular distribution
of TLR2 and TLR4 is altered in diabetic CAECs. Alterna-
tively, T1D may alter the efficiency of post-receptor sig-
naling. TLR2 and TLR4 share the myeloid differentiation
primary response gene (MyD)88-mediated pathway to
activate NF-B. In this signaling pathway, MyD88
recruits interleukin-1 receptor-associated kinase (IRAK),
leading to the activation of tumor necrosis factor recep-
tor-activated factor (TRAF)-6, and TRAF-6 subsequently
activates NF-B [42,43]. It is possible that the MyD88
pathway becomes more efficient to transduce TLR2 and
TLR4 signal in diabetic cells. In this regard, reactive oxy-
gen species (ROS) plays a critical role in activating pro-
inflammatory signaling pathways downstream of TLR2
and TLR4 [44,45] and enhances the activity of NF-B
[46]. Elevated generation of ROS in diabetic CAECs in
response to TLR2 and TLR4 stimulation may augment
NF-B activation and the resultant expression of inflam-
matory mediators. Nevertheless, further studies are
needed to explain why diabetic CAECs exhibit enhanced
TLR2/4 responses in the absence of increased levels of
these receptors.
Insulin alone is insufficient to suppress the hyper-
inflammatory responses in diabetic CAECs
There are distinct insulin receptors and post-receptor
signaling pathways in CAECs [47,48], and atherosclero-
tic lesions are worsened in mice lacking endothelial
insulin signaling [48]. To determine whether the
enhanced inflammatory responses could be corrected by
insulin, we stimulated T1D cells with PGN and LPS in
the presence of insulin. The normal range of blood insu-
lin has been reported to be 7-24 mU/l, and treatment
with 10 U/l of insulin reduces the levels of glycosamino-
glycan in cultured endothelial cells [49]. We applied
insulin at 10 and 100 U/l to diabetic cells prior to sti-
mulation with a TLR2 or TLR4 agonist. We found that
insulin at 10 U/l had no effect on ICAM-1, IL-6 and IL-
8 levels following stimulation with either PGN or LPS.
Higher concentration of insulin (100 U/l) did not affect
LPS-induced production of ICAM-1, IL-6 and IL-8
although it attenuated PGN-induced ICAM-1 and IL-6
production. Therefore, insulin alone in a concentration
of 10 U/l could not correct the hyper-inflammatory
responses to both TLR2 and TLR4 agonists. A higher
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TLR4-mediated inflammatory responses although it
reduced ICAM-1 and IL-6 levels following TLR2 stimu-
lation. It has been reported that a large dose of insulin
attenuates systemic inflammatory response in endotoxe-
mic mice [50]. It is likely that insulin is potent in sup-
pression of the TLR4-mediated inflammatory response
in circulating leukocytes. Since cells are treated with
insulin in the absence of glucose, it remains unclear
whether a lower concentration of insulin, in the pre-
sence of glucose, suppresses the inflammatory response
in diabetic CAECs.
Conclusions
In conclusion, the results of the present study show:
1) stimulation of TLR2 and TLR4 induces greater
expression of IL-6, IL-8 and ICAM-1 in T1D CAECs, 2)
the enhanced inflammatory responses to TLR2 and
TLR4 agonists in diabetic CAECs correlate with aug-
mented NF-B activation in the absence of an alteration
of cellular TLR2 and TLR4 protein levels, and 3) insulin
alone is insufficient to suppress the hyper-inflammatory
responses to both TLR2 and TLR4 agonists in diabetic
CAECs. Since CAECs have an important role in the
development of atherosclerosis, an inflammatory disease
[51,52], our findings suggest that the pro-inflammatory
phenotype of T1D CAECs may be one of the factors
contributing to the higher risk for coronary artery ather-
osclerosis in T1D patients.
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